332 results about "Disease gene" patented technology

A method of producing a homogenous population of homozygous stem (HS) cells pre-selected for immunotype and / or genotype from donor cells is described herein. The invention relates to methods of using immunohistocompatible HS cells for diagnosis, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, traumatic injuries and cancer. The invention further relates to methods for using histocompatible HS stem cells pre-selected for a non-disease genotype for prophylactic and therapeutic intervention including, but not limited to, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, and cancer. Furthermore, the invention relates to a catalogued transplant depository of HS cells derived from multiple donors, each of the HS cells being homozygous for a unique HLA haplotype, for the purpose of having a constant, reliable, comprehensive supply of immunohistocompatible cells for diagnosis, treatment and / or transplantation.

Methods, systems and equipment for diagnosing or monitoring the progression or treatment of AML or MDS. This invention identifies a plurality of AML or MDS disease genes which are differentially expressed in bone marrow cells of AML or MDS patients as compared to disease-free humans. These AML or MDS disease genes can be used as molecular markers for detecting the presence or absence of AML or MDS. These genes can also be used for the early identification of MDS patients who eventually progress to AML.

The invention discloses a design way of primers for in-vitro qualitative detection of newborn inherited metabolic disease genes. The design way comprises the following steps: (1) acquiring relevant disease-causing gene information of inherited diseases: acquiring the relevant disease-causing gene information, including gene location information and mutation site information of a plurality of inherited diseases through an OMIM (Online Mendelian Inheritance in Man) database, and acquiring exon and intron information of relevant genes from an NCBI (National Center for Biotechnology Information) database according to the obtained gene information; (2) designing primers specific to the relevant genes: designing corresponding specific primers F1 and R1 specific to an exon and an exon-intron combination area of each gene. The invention also discloses the first-round PCR (Polymerase Chain Reaction) primer sequence list of syndromic deafness, a first-round PCR primer list of G6PD genes, and a first-round PCR primer sequence list of SLC12A3 genes. The primers can be used for detecting relevant genes of 22 types of common newborn inherited diseases.

The present invention provides methods, systems and equipment for the prognosis, diagnosis and selection of treatment of AML or other types of leukemia. Genes prognostic of clinical outcome of leukemia patients can be identified according to the present invention. Leukemia disease genes can also be identified according to the present invention. These genes are differentially expressed in PBMCs of AML patients relative to disease-free humans. These genes can be used for the diagnosis or monitoring the development, progression or treatment of AML.

The invention discloses a method for recognizing a key regulator in a gene co-regulatory network based on a linear model. The gene expression profile data and the gene regulation relation data are utilized to forecast the expression of the known disease gene in the manner of establishing the linear model, so as to complete the recognition for the key regulator in the gene co-regulatory network. The method provided by the invention is simply realized; the key regulator in the gene co-regulatory network can be accurately recognized only according to the gene expression profile data and the gene regulation relation; tests prove that the recognized regulator has an important biological significance and has important theoretical significance and practical value in researching the disease mechanism.

The present invention relates to the identification of p53 biomarker profiles that predict response in patients with hyperproliferative disease such as cancer to a therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy.

The invention belongs to the technical field of biological products, and relates to a genetic diagnosis reagent for the Citrin deficiency disease and an application of the genetic diagnosis reagent. The quantitative PCR technology of Taqman MGB probes is used for detecting one or more of nine mutation sites of a Citrin deficiency disease gene SLC25A13, and therefore the majority of pathogenic mutations can be detected. According to the genetic diagnosis reagent for the Citrin deficiency disease, a quantitative PCR instrument and a common PCR reagent can be used; the nine Citrin deficiency disease mutant genetic loci are detected in an amplification mode so that a detection result can be obtained within 3-5 hours; the genetic diagnosis reagent can be used for detecting the Citrin deficiency disease in a single laboratory closed tube provided with the quantitative PCR instrument, thereby avoiding the situation that high concentration samples are contaminated; moreover, the genetic diagnosis reagent can be conveniently produced in a biotechnological company and used for detection in a biomedical detection mechanism, thereby meeting the requirement for industrialization promotion.

The invention discloses a breeding method for a multi-resistance hibiscus cannabinus variety, belonging to the technical field of hibiscus cannabinus disease resistance breeding. The breeding method comprises the steps that a high-yield hibiscus cannabinus variety is taken as a recurrent parent, the recurrent parent is respectively hybridized with an anthracnose resistant source parent, a root knot nematode disease resistant source parent and a gray mould resistant source parent, firstly the three main hibiscus cannabinus disease genes are respectively imported into one high-yield hibiscus cannabinus variety by adopting a hybridization back-crossing method, then the three main hibiscus cannabinus disease genes are polymerized together by adopting a hybridization re-crossing method, and finally a hibiscus cannabinus variety which is resistant to three diseases at the same time is bred. The multi-resistance hibiscus cannabinus variety bred by adopting the breeding method is good in resistance and high in yield, application amount of a pesticide can be obviously reduced, and the yield is increased while environmental pollution can also be reduced. By adopting the breeding method disclosed by the invention, the three main hibiscus cannabinus disease genes resistant to anthracnose, root knot nematode disease and gray mould can be polymerized together, the hibiscus cannabinus variety which is resistant to the three diseases at the same time can be bred, and cost for pesticide application and labour each mu is reduced, investment of farmers is reduced, income of the farmers is increased, and environmental pollution is reduced.